Saturday, October 31, 2026

GBP/EUR Bullish Momentum: 0.97% Up In The Last 10 Sessions

GBP/EUR Bullish Momentum: 0.97% Up In The Last 10 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 0.97% for the last 10 sessions. At 04:08 EST on Friday, 5 May, GBP/EUR (GBPEUR) is $1.14.

GBP/EUR's yearly highs and lows, it's 5.715% up from its 52-week low and 4.654% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was 0.42%, 0.07%, and 0.28%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.42% (last week), 0.24% (last month), and 0.28% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy seesaws around 135.30 on fed’s hike as it opens the door for a pause. According to FXStreet on Wednesday, 3 May, "The USD/JPY 1-hour chart portrays that the pair fell below its prior low of 135.07 and printed a new one at 134.83. ", "The USD/JPY extended its losses past the prior's day low of 135.07, collapsing down the 135 figure, as the US Federal Reserve (Fed) decided to raise rates by 25 bps, though it signaled that it would pause its cycle. "
  • Usd/jpy plunges more than 1%, below 136.00 amidst the uncertainty of the fomc’s decision. According to FXStreet on Wednesday, 3 May, "The USD/JPY tumbled for the second day in a row, influenced by the fall in the US 10-year Treasury bond yield amidst a mixed market sentiment spurred by the Federal Reserve's (Fed) monetary policy decision looming. ", "The Federal Reserve would unveil its decision ahead of the session, followed by Chair Powell's press conference, which USD/JPY traders widely expect."
  • Usd/jpy price analysis: set for further downside past 136.00 as fed decision looms. According to FXStreet on Wednesday, 3 May, "Adding strength to the downside bias is the descending RSI (14) line that currently seesaws near the 50.0 level, which in turn suggests the continuation of the latest weakness in the USD/JPY price.", "However, the resistance-turned-support line from late March, around 135.70 at the latest, restricts the immediate downside of the USD/JPY pair."
  • Usd/jpy slides below 136.00, fresh weekly low amid reviving safe-haven demand, weaker USD. According to FXStreet on Wednesday, 3 May, "That said, a big divergence in the monetary policy stance adopted by the Bank of Japan (BoJ) and the Federal Reserve (Fed) could help limit the downside for the USD/JPY pair, at least for the time being. ", "The uncertainty, meanwhile, might hold back traders from placing aggressive bets around the USD/JPY pair ahead of the highly-anticipated FOMC decision, due to be announced later during the US session. "
  • Usd/jpy finds intermediate support around 134.40 as focus shifts to US NFP. According to FXStreet on Thursday, 4 May, "The USD/JPY pair has gauged an intermediate cushion after a perpendicular sell-off to near 134.40 in the Asian session. "

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com